Lauren Pommert

12PUBLICATIONS
42CO-AUTHORS
Gene and molecular therapyNanotoxicology, health and safetyEpidemiological modellingCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jul 31, 2024
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients.

Francis R LeBlanc, Erin H Breese, Karen C Burns

|Jul 23, 2024
Toxicity profile of high-dose methotrexate in young children with central nervous system tumors.

Ashley N Chavana, Zachary L Taylor, Nicholas DeGroote

|Jul 28, 2023
Clinical covariates that improve the description of high dose methotrexate pharmacokinetics in a diverse population to inform MTXPK.org.

Zachary L Taylor, Tamara P Miller, Ethan A Poweleit

|Jan 25, 2023
Use of gemcitabine, oxaliplatin, and anti-CD20 therapy in children and adolescents with non-Hodgkin lymphoma unfit for intensive therapy.

Jonathan D Bender, Jeremy D Rubinstein, Benjamin Mizukawa

|Jun 21, 2022
Real-world experience in treating pediatric relapsed/refractory or therapy-related myeloid malignancies with decitabine, vorinostat, and FLAG therapy based on a phase 1 study run by the TACL consortium.

Eric S Schafer, Karen Chao, Alexandra M Stevens

|Feb 18, 2022
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.

Lauren Pommert, Eric S Schafer, Jemily Malvar

Pageof 2

Frequent Collaborators

3 joint publications

Jeremy Rubinstein

2 joint publications

Melanie B Bernhardt

2 joint publications

Laura B Ramsey

2 joint publications

Tamara P Miller